|PharmacoGx: an R package for analysis of large pharmacogenomic datasets|
P Smirnov, Z Safikhani, N El-Hachem, D Wang, A She, C Olsen, ...
Bioinformatics 32 (8), 1244-1246, 2016
|Identification of predictive markers of response to the MEK1/2 inhibitor selumetinib (AZD6244) in K-ras–mutated colorectal cancer|
JJ Tentler, S Nallapareddy, AC Tan, A Spreafico, TM Pitts, MP Morelli, ...
Molecular cancer therapeutics 9 (12), 3351-3362, 2010
|Rational combination of a MEK inhibitor, selumetinib, and the Wnt/calcium pathway modulator, cyclosporin A, in preclinical models of colorectal cancer|
A Spreafico, JJ Tentler, TM Pitts, AC Tan, MA Gregory, JJ Arcaroli, ...
Clinical Cancer Research 19 (15), 4149-4162, 2013
|Overcoming IGF1R/IR resistance through inhibition of MEK signaling in colorectal cancer models|
SA Flanigan, TM Pitts, TP Newton, GN Kulikowski, AC Tan, MC McManus, ...
Clinical cancer research 19 (22), 6219-6229, 2013
|Predictive biomarkers of sensitivity to the aurora and angiogenic kinase inhibitor ENMD-2076 in preclinical breast cancer models|
JR Diamond, SG Eckhardt, AC Tan, TP Newton, HM Selby, KL Brunkow, ...
Clinical Cancer Research 19 (1), 291-303, 2013
|A short survey of computational analysis methods in analysing ChIP-seq data|
H Kim, J Kim, H Selby, D Gao, T Tong, TL Phang, AC Tan
Human genomics 5 (2), 117, 2011
|Association of the epithelial-to-mesenchymal transition phenotype with responsiveness to the p21-activated kinase inhibitor, PF-3758309, in colon cancer models|
TM Pitts, GN Kulikowski, AC Tan, BW Murray, JJ Arcaroli, JJ Tentler, ...
Frontiers in pharmacology 4, 35, 2013
|A survey of statistical software for analysing RNA-seq data|
D Gao, J Kim, H Kim, TL Phang, H Selby, AC Tan, T Tong
Human genomics 5 (1), 56, 2010
|Utilization of quantitative in vivo pharmacology approaches to assess combination effects of everolimus and irinotecan in mouse xenograft models of colorectal cancer|
EL Bradshaw-Pierce, TM Pitts, G Kulikowski, H Selby, AL Merz, ...
PloS one 8 (3), 2013
|BatchQC: interactive software for evaluating sample and batch effects in genomic data|
S Manimaran, HM Selby, K Okrah, C Ruberman, JT Leek, J Quackenbush, ...
Bioinformatics 32 (24), 3836-3838, 2016
|Antitumor activity of the MEK inhibitor TAK-733 against melanoma cell lines and patient-derived tumor explants|
LN Micel, JJ Tentler, AC Tan, HM Selby, KL Brunkow, KM Robertson, ...
Molecular cancer therapeutics 14 (2), 317-325, 2015
|Combined inhibition of MEK and Aurora A kinase in KRAS/PIK3CA double-mutant colorectal cancer models|
SL Davis, KM Robertson, TM Pitts, JJ Tentler, EL Bradshaw-Pierce, ...
Frontiers in pharmacology 6, 120, 2015
|Targeting the protein ubiquitination machinery in melanoma by the NEDD8-activating enzyme inhibitor pevonedistat (MLN4924)|
KM Wong, LN Micel, HM Selby, AC Tan, TM Pitts, SM Bagby, A Spreafico, ...
Investigational new drugs 35 (1), 11-25, 2017
|Antitumor activity of the aurora a selective kinase inhibitor, alisertib, against preclinical models of colorectal cancer|
TM Pitts, EL Bradshaw, SM Bagby, SL Hyatt, HM Selby, A Spreafico, ...
Oncotarget 7 (31), 50290, 2016
|Antitumor activity of a potent MEK inhibitor, TAK-733, against colorectal cancer cell lines and patient derived xenografts|
CH Lieu, PJ Klauck, PK Henthorn, JJ Tentler, AC Tan, A Spreafico, ...
Oncotarget 6 (33), 34561, 2015
|Rational design and identification of immuno-oncology drug combinations|
MAJ Iafolla, H Selby, K Warner, PS Ohashi, B Haibe-Kains, LL Siu
European Journal of Cancer 95, 38-51, 2018
|Antitumor activity of the polo-like kinase inhibitor, TAK-960, against preclinical models of colorectal cancer|
PJ Klauck, SM Bagby, A Capasso, EL Bradshaw-Pierce, HM Selby, ...
BMC cancer 18 (1), 136, 2018
|Abstract B178: Molecular determinants of response to the investigational small molecule inhibitor of Nedd8-activating enzyme (NAE) MLN4924 in melanoma cell lines and patient …|
JJ Tentler, LN Micel, HM Selby, AC Tan, KL Brunkow, TM Pitts, ...
Molecular Cancer Therapeutics 10 (11 Supplement), B178-B178, 2011
|393 TAK-733, an Investigational Novel MEK Inhibitor, Suppresses Colorectal Cancer (CRC) Tumor Growth in Biomarker Positive Patient-derived Human Tumor Explants|
CH Lieu, JL Tentler, AC Tan, TM Pitts, A Spreafico, HM Selby, ...
European Journal of Cancer 48, 119-120, 2012
|Know Thy cells: inferring phenotype from genotype|